The rise of Viagra initially drove a surge for pharma, but recent changes present a uncertain picture for investors. Off-patent competitors are reducing revenue, and persistent legal battles add more complexity to the https://deborahmong042677.newsbloger.com/41799441/the-blue-pill-and-the-pharmaceutical-industry-a-volatile-investment